On March 17, 1995, the Food and Drug Administration licensed
Varicella Virus Vaccine, Live (VARIVAX {registered symbol}),
manufactured and distributed by Merck and Co., Inc., (Rahway, New
Jersey). This vaccine has been licensed for use in persons aged
greater than or equal to 12 months. The recommended dose for
susceptible children aged 12 months-12 years is one 0.5 mL dose
administered subcutaneously. The recommended dosage for susceptible
adolescents aged greater than or equal to 13 years and adults is
two 0.5 mL doses of vaccine 4-8 weeks apart.
The recommendations of the Advisory Committee on Immunization
Practices on the use of varicella vaccine will be published.
Reported by: Center for Biologics Evaluation and Research, Food and
Drug Administration. National Immunization Program, CDC.
Disclaimer
All MMWR HTML versions of articles are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the electronic PDF version and/or the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.
